A Key Link for Transmission Prevention (MP3)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This pilot study will assess the feasibility for the potential public health benefit of behavioral and antiretroviral interventions during acute HIV infection.
Central Hypothesis The investigators hypothesize that delivering behavioral and antiretroviral interventions to acutely infected persons will reduce onward transmission.
| Condition | Intervention |
|---|---|
|
HIV |
Behavioral: Standard HIV prevention messages Behavioral: BI: Information-Motivation-Behavioral Skills Model Drug: Raltegravir Drug: emtricitabine/tenofovir disoproxil fumarate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study |
- Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening [ Time Frame: 1 year ]
- Prevalence of AHI Among Persons Screened [ Time Frame: 1 year ]Prevalence of AHI among all persons screened. This measure is among all persons screened, prior to randomization.
- Proportion of Persons With AHI Successfully Recruited Into the Study [ Time Frame: 1 year ]This outcome reflects the ability to recruit persons with AHI into a study. The outcome is based on the population prior to randomization.
- Proportion of Participants Completing Full Course of ARVs in Arm BIA [ Time Frame: 1 year ]Proportion of participants in the BIA arm receiving full course of ARVs. This outcome is calculated among the BIA arm only, as that
- Proportion of Participants in Arm BI and BIA (Combined) Who Complete the 4 Behavioral Sessions Within 3 Weeks of Enrollment. [ Time Frame: 1 year ]In this pilot study, we addressed our ability to complete the behavioral intervention quickly. As two arms received the behavioral intervention, this outcome is combined across those two arms.
- Proportion of Persons Completing All Scheduled Visits in Each Study Arm [ Time Frame: 1 year ]
- Number of Adverse Events [ Time Frame: one year ]Mean number of adverse events per group
- Unprotected Sex Acts in Previous One Week - 12 Weeks [ Time Frame: 12 weeks ]The mean number of unprotected sex acts in previous one week, assessed at 12 weeks
- Unprotected Sex Acts in Previous One Week - 26 Weeks [ Time Frame: 26 weeks ]The mean number of unprotected sex acts in previous one week, assessed at 26 weeks
- Unprotected Sex Acts in Previous One Week - 52 Weeks [ Time Frame: 52 weeks ]The mean number of unprotected sex acts in previous one week, assessed at 52 weeks
- Unprotected Sex Acts in Previous One Month - 12 Weeks [ Time Frame: 12 weeks ]The mean number of unprotected sex acts in previous one month, assessed at 12 weeks
- Unprotected Sex Acts in Previous One Month - 26 Weeks [ Time Frame: 26 weeks ]The mean number of unprotected sex acts in previous one month, assessed at 26 weeks
- Unprotected Sex Acts in Previous One Month - 52 Weeks [ Time Frame: 52 weeks ]The mean number of unprotected sex acts in previous one month, assessed at 52 weeks
- Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite) [ Time Frame: 26 weeks ]Cumulative incidence, definied as at least one incident infection with either gonorrhea, chlamydia or trichomoniasis
- Cumulative Incidence of Gonorrhea, Chlamydial Infection and Trichomoniasis (Composite) [ Time Frame: 52 weeks ]At least one incident infection with either gonorrhea, chlamydia or trichomoniasis
- Cumulative Incidence Herpes Simplex Virus Type 2 [ Time Frame: 26 weeks ]cumulative incidence of herpes simplex virus type 2, assessed at 26 weeks. Persons with baseline positivity were excluded.
- Cumulative Incidence Herpes Simplex Virus Type 2 [ Time Frame: 52 weeks ]cumulative incidence of herpes simplex virus type 2, assessed at 52 weeks. Persons with baseline positivity were excluded.
- Number of Partners Reporting for HIV Testing [ Time Frame: 52 weeks ]Number of partners per index reporting for HIV testing at any time during follow-up
- Proportion of Partners Reporting for HIV Testing [ Time Frame: 52 weeks ]Proportion of sexual partners reporting for HIV testing among all sexual partners named by the index participants
- Suppression of HIV RNA to <1000c/ml at 12 Weeks [ Time Frame: 12 weeks ]Proportion of persons in each arm with viral load <1000copies/ml at 12 weeks
- Time to HIV RNA Suppression <1000 c/ml [ Time Frame: From date of randomization until viral load suppression, up to 52 weeks ]median time to viral load suppression (<1000 c/ml)
- Blood HIV RNA Concentration at Week 12 [ Time Frame: 12 weeks ]
- Blood HIV RNA Concentration at Week 26 [ Time Frame: 26 weeks ]
- Blood HIV RNA Concentration at Week 52 [ Time Frame: 52 weeks ]
- Genital HIV RNA Concentration - Week 12, Women [ Time Frame: 12 weeks ]median HIV RNA concentration in cervical lavage fluid
- Genital HIV RNA Concentration - Week 26, Women [ Time Frame: 26 weeks ]median HIV RNA concentration in cervical lavage fluid
- Genital HIV RNA Concentration - Week 52, Women [ Time Frame: 52 weeks ]median HIV RNA concentration in cervical lavage fluid
- Genital HIV RNA Concentration - Week 12, Men [ Time Frame: 12 weeks ]median HIV RNA concentration as measured in semen
- Genital HIV RNA Concentration - Week 26, Men [ Time Frame: 26 weeks ]median HIV RNA concentration as measured in semen
- Genital HIV RNA Concentration - Week 52, Men [ Time Frame: 52 weeks ]median HIV RNA concentration as measured in semen
| Enrollment: | 46 |
| Study Start Date: | October 2011 |
| Study Completion Date: | July 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Standard Counseling Arm
The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
|
Behavioral: Standard HIV prevention messages
A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
|
|
Active Comparator: Behavioral Intervention Arm only
Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
|
Behavioral: Standard HIV prevention messages
A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
Behavioral: BI: Information-Motivation-Behavioral Skills Model
The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
|
|
Active Comparator: Behavioral Intervention plus ARV
The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
|
Behavioral: Standard HIV prevention messages
A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
Behavioral: BI: Information-Motivation-Behavioral Skills Model
The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
Drug: Raltegravir
raltegravir (400 mg) administered orally twice daily for 12 weeks
Other Name: Isentress, RAL
Drug: emtricitabine/tenofovir disoproxil fumarate
emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
Other Name: Truvada, FTC/TDF
|
Detailed Description:
The HIV epidemic in sub-Saharan Africa is severe and continues to grow. In urban areas of Malawi, 19% of pregnant women seeking antenatal care and 15.6% of Malawians aged 15-49 years were infected with HIV in 2007. Prevention interventions that prevent onward transmission of HIV are urgently needed.
Persons with acute HIV infection (AHI) may be responsible for a substantial proportion of onward transmission of HIV infection. AHI is characterized by unfettered replication of HIV in a "ramp up viremia". The high concentration of HIV in blood and genital secretions remains elevated for up to 10-12 weeks before it declines to the levels observed in established infection. These high levels of HIV shedding in the genital tract are likely to produce very efficient sexual transmission and the proportion of virions that are infectious may be substantially higher during acute compared to chronic infection. Consequently, the probability of transmission during unprotected intercourse for those with AHI is very high. Identifying persons with AHI and intervening to reduce onward transmission represents a tantalizing, but unproven, opportunity for HIV prevention.
To have maximal impact, a prevention program targeting AHI must identify a substantial number of acutely infected persons and intervene quickly to minimize onward transmission. An effective immediate intervention would require behavioral modification to limit sexual partners and unprotected sex acts, and a biological intervention to reduce infectious viral burden in genital secretions. This is the first study to pilot a combined behavioral and biomedical intervention in individuals with AHI to reduce onward transmission of HIV.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Primary participants:
- Acute HIV-1 infection
- Men and women age greater than/= 18 years.
- Intention to remain in the Lilongwe area for the duration of the study.
- Ability and willingness of participant to provide informed consent.
- Willingness to provide contact/locator information, be contacted, and asked to return for AHI results.
Partner Participants:
- Referred by a primary participant and present with a referral card.
- Had vaginal or anal sex with a primary participant within 12 weeks prior to that primary participant's enrolling
- Men and women age greater than/=18 years.
- remain in the Lilongwe area for the duration of the study.
- Ability and willingness of participant to provide informed consent.
Exclusion Criteria:
Primary Participants:
- HIV infection based on two positive HIV antibody rapid tests at the time of screening.
- HIV-negative based on one or more antibody rapid test and an HIV RNA PCR test.
- Serious illness, including tuberculosis or opportunistic infection, requiring systemic treatment and/or hospitalization.
- Active drug or alcohol use or dependence.
- Current imprisonment or involuntary incarceration.
- Any other condition that in the opinion of the study investigator would compromise the safety of the study participant or study staff, or would prevent proper conduct of the study.
Partner Participants:
- Active drug or alcohol use or dependence.
- Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness.
Exclusion for Receipt of Antiretroviral Drugs in the BIA Arm
Note:A key component of this pilot study is to estimate the potential effect of ARVs during acute infection when applied on a large population scale.In effect, this pilot study should be viewed as a pilot for an effectiveness trial. Consequently, we will randomize all eligible participants to one of the three arms. If, however, persons should not receive ARVs for a variety of medically-related reasons, these persons will remain in the BIA arm, but will not receive ARVs. Women who are of reproductive potential but who refuse to use at least one form of contraception (see below), will remain in the BIA arm but will not receive ARVs. Similarly, persons randomized to the BI arm who do not attend all sessions will remain in the BI arm.
Persons randomized to BIA with any of the following conditions will be excluded from receiving ARVs, but will remain in the BIA group for purposes of analysis.
- Laboratory values obtained at Day 0 prior to initiating ARVs at a subsequent visit
- Absolute neutrophil count <300/mm3
- Hemoglobin <8.0 g/dL
- Platelet count <40,000/mm3
- Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase > 5 x upper limit of normal (ULN)
- Total bilirubin >2.5 x ULN
- Creatinine Clearance (CrCl) <60 mL/min
- Hepatitis B surface antigen positivity
- Positive serum or urine pregnancy test at Day 0.
- Breastfeeding
- Refusal to use at least one method of contraception, if a woman is of reproductive potential.
Acceptable forms of contraception include: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, intrauterine device (IUD), or a hormonal-based contraceptive.
Women not meeting the reproductive potential criteria above may receive the study drugs without using contraception.
- Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.
- Requirement for any current medications that are prohibited with any study drugs.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01450189
| Malawi | |
| Lighthouse Trust, Kamuzu Central Hospital | |
| Lilongwe, Malawi | |
| UNC Project | |
| Lilongwe, Malawi | |
| Study Chair: | William C Miller, MD, PhD, MPH | University of North Carolina, Chapel Hill |
| Study Chair: | Audrey Pettifor, PhD, MPH | University of North Carolina, Chapel Hill |
| Principal Investigator: | Sam Phiri, PhD, MSc | Kamuzu Central Hospital, Lilongwe, Malawi |
More Information
| Responsible Party: | William (Bill) C. Miller, MD, PI, University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT01450189 History of Changes |
| Other Study ID Numbers: |
11-0815 CID 1002 ( Other Identifier: UNC at Chapel Hill ) |
| Study First Received: | September 18, 2011 |
| Results First Received: | January 13, 2016 |
| Last Updated: | November 4, 2016 |
Keywords provided by William (Bill) C. Miller, MD, University of North Carolina, Chapel Hill:
|
Acute HIV Transmission Prevention Randomized Pilot study |
Additional relevant MeSH terms:
|
Tenofovir Emtricitabine Raltegravir Potassium Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors |
Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents HIV Integrase Inhibitors Integrase Inhibitors |
ClinicalTrials.gov processed this record on May 25, 2017